Filing Flows › Medpace Holdings (MEDP) › How it makes money
How Medpace Holdings (MEDP) makes money
Medpace Holdings (MEDP) made $716M of revenue in the third quarter 2026 (Q3 2026), +9% from a year earlier. Metabolic brought in $230M (32%); Other brought in $209M (29%); Oncology brought in $100M (14%). Of every dollar of revenue, 23¢ was left as operating profit, 19¢ was left as net earnings.
Drawing the Sankey…
Revenue by segment, Q3 2026
| Segment | Revenue | Share | Q/Q | Y/Y |
|---|---|---|---|---|
| Metabolic | $230M | 32.1% | +10% | +19% |
| Other | $209M | 29.2% | -4% | +5% |
| Oncology | $100M | 14.0% | +2% | -6% |
| Cardiology | $83.6M | 11.7% | +1% | +27% |
| Central Nervous System | $61.4M | 8.6% | +2% | +3% |
| AVAI | $31.8M | 4.4% | -16% | -13% |
Where each dollar of revenue goes
| Line | Q3 2026 | % of revenue |
|---|---|---|
| Revenue | $716M | 100.0% |
| Operating profit | $166M | 23.1% |
| Income tax | $33.4M | 4.7% |
| Net earnings | $137M | 19.2% |
| Operating cash flow | $217M | 30.3% |
| Free cash flow | $196M | 27.4% |
Revenue, quarter by quarter
| Quarter | Revenue | Y/Y |
|---|---|---|
| Q3 2026 | $716M | +8% |
| Q2 2026 | $707M | +17% |
| Q1 2026 | $707M | +26% |
| Q4 2025 | $708M | +32% |
| Q3 2025 | $660M | +24% |
| Q2 2025 | $603M | +14% |
| Q1 2025 | $559M | +9% |
From Medpace Holdings' 10-Q filed Oct 22, 2026 (on EDGAR).
Questions
How does Medpace Holdings make money?
Medpace Holdings (MEDP) made $716M of revenue in the third quarter 2026 (Q3 2026), +9% from a year earlier. Metabolic brought in $230M (32%); Other brought in $209M (29%); Oncology brought in $100M (14%). Of every dollar of revenue, 23¢ was left as operating profit, 19¢ was left as net earnings.
What is Medpace Holdings' biggest business?
Metabolic: $230M in the third quarter 2026, 32% of revenue, +19% from a year earlier.
What is Medpace Holdings' profit margin?
Net earnings were $137M, 19.2% of revenue, in the third quarter 2026; the operating margin was 23.1%.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.